Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
Aardvark Therapeutics (NASDAQ:AARD) announced its participation in the 2025 United in Hope Conference for Prader-Willi syndrome (PWS) from June 24-28 in Phoenix, Arizona.
The company will present previously disclosed Phase 2 data for ARD-101, highlighting the drug's favorable safety profile and early evidence of reduced hyperphagia in PWS patients. The presentation will also discuss how these findings informed their ongoing Phase 3 HERO study.
Chief Medical Officer Dr. Manasi Jaiman will participate in a panel discussion about the Phase 3 HERO study, and company representatives will be available at their booth to engage with attendees.
Aardvark Therapeutics (NASDAQ:AARD) ha annunciato la sua partecipazione alla conferenza United in Hope 2025 dedicata alla sindrome di Prader-Willi (PWS), che si terrà dal 24 al 28 giugno a Phoenix, Arizona.
L'azienda presenterà i dati di Fase 2 per ARD-101 già resi noti, evidenziando il profilo di sicurezza favorevole del farmaco e le prime prove di una riduzione dell'iperfagia nei pazienti con PWS. La presentazione illustrerà inoltre come questi risultati abbiano influenzato lo studio in corso di Fase 3 HERO.
La Direttrice Medica, la Dott.ssa Manasi Jaiman, parteciperà a una tavola rotonda sullo studio di Fase 3 HERO, mentre i rappresentanti dell'azienda saranno presenti allo stand per interagire con i partecipanti.
Aardvark Therapeutics (NASDAQ:AARD) anunció su participación en la conferencia United in Hope 2025 para el síndrome de Prader-Willi (PWS), que se llevará a cabo del 24 al 28 de junio en Phoenix, Arizona.
La compañía presentará datos previamente divulgados de la Fase 2 para ARD-101, destacando el perfil de seguridad favorable del medicamento y las primeras evidencias de reducción de la hiperfagia en pacientes con PWS. La presentación también abordará cómo estos hallazgos han informado su estudio en curso de Fase 3 HERO.
La directora médica, la Dra. Manasi Jaiman, participará en una mesa redonda sobre el estudio de Fase 3 HERO, y los representantes de la compañía estarán disponibles en su stand para interactuar con los asistentes.
Aardvark Therapeutics (NASDAQ:AARD)는 2025년 6월 24일부터 28일까지 애리조나주 피닉스에서 열리는 프래더-윌리 증후군(PWS) 연합 희망 컨퍼런스에 참가한다고 발표했습니다.
회사는 이전에 공개한 ARD-101의 2상 데이터를 발표할 예정이며, 이 약물의 우수한 안전성 프로필과 PWS 환자에서 과식증 감소에 대한 초기 증거를 강조할 것입니다. 발표에서는 이러한 결과가 진행 중인 3상 HERO 연구에 어떻게 반영되었는지도 다룰 예정입니다.
수석 의학 책임자인 마나시 자이만 박사가 3상 HERO 연구에 관한 패널 토론에 참여하며, 회사 대표들은 부스에서 참석자들과 소통할 예정입니다.
Aardvark Therapeutics (NASDAQ:AARD) a annoncé sa participation à la conférence United in Hope 2025 sur le syndrome de Prader-Willi (PWS), qui se tiendra du 24 au 28 juin à Phoenix, Arizona.
L'entreprise présentera des données de Phase 2 pour ARD-101 déjà communiquées, mettant en avant le profil de sécurité favorable du médicament ainsi que les premières preuves d'une réduction de l'hyperphagie chez les patients atteints de PWS. La présentation expliquera également comment ces résultats ont guidé leur étude en cours de Phase 3 HERO.
La directrice médicale, le Dr Manasi Jaiman, participera à une table ronde sur l'étude de Phase 3 HERO, et les représentants de l'entreprise seront présents à leur stand pour échanger avec les participants.
Aardvark Therapeutics (NASDAQ:AARD) gab bekannt, dass es an der United in Hope Konferenz 2025 für das Prader-Willi-Syndrom (PWS) vom 24. bis 28. Juni in Phoenix, Arizona, teilnehmen wird.
Das Unternehmen wird zuvor veröffentlichte Phase-2-Daten für ARD-101 präsentieren, die das günstige Sicherheitsprofil des Medikaments und erste Hinweise auf eine Verringerung der Hyperphagie bei PWS-Patienten hervorheben. Die Präsentation wird auch erläutern, wie diese Erkenntnisse die laufende Phase-3-HERO-Studie beeinflusst haben.
Die Chief Medical Officer, Dr. Manasi Jaiman, wird an einer Podiumsdiskussion zur Phase-3-HERO-Studie teilnehmen, und Unternehmensvertreter stehen am Stand für Gespräche mit den Teilnehmern zur Verfügung.
- None.
- None.
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that members of its team will join the Prader-Willi syndrome (PWS) community at the 2025 United in Hope Conference, taking place June 24 to 28 in Phoenix, Arizona.
“It’s an honor to stand alongside the families, advocates, scientists and clinicians who are working to transform the lives of those affected by PWS,” said Dr. Tien Lee, Chief Executive Officer of Aardvark Therapeutics. “The United in Hope Conference is a powerful reflection of the passion, resilience and shared purpose that drive our mission. We’re proud to contribute to the clinical dialogue and deeply value the opportunity to strengthen our partnership with this extraordinary community.”
During the clinical and scientific program, Aardvark will present previously disclosed data from its Phase 2 study of ARD-101 in PWS in both a poster and a five-minute “lightning” oral presentation, both entitled “Reduction in Hyperphagia in the ARD-101 Phase 2 Clinical Trial Informs Phase 3 HERO Trial in PWS.” The presentations will highlight ARD-101’s favorable safety profile in PWS as well as early evidence for reduced hyperphagia, all of which informed the design of the ongoing Phase 3 HERO study, which is currently enrolling patients with PWS.
Within the family program agenda, Aardvark’s Chief Medical Officer, Manasi Jaiman, M.D., will join a panel of clinicians to discuss the details of the company’s ongoing Phase 3 HERO study.
Additional members of the company’s medical and advocacy team invite the medical community and families attending to engage with attending team members at the company’s booth to learn more about ARD-101, the HERO study and the company’s commitment to the PWS community.
About Aardvark Therapeutics, Inc.
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome and metabolic diseases. Recognizing hunger (the discomfort from not having eaten recently) is a distinct neural signaling pathway separate from appetite (the reward-seeking, desirability of food). Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. Our lead compound, oral ARD-101, is in Phase 3 clinical development for the treatment of hyperphagia associated with PWS, a rare disease characterized by insatiable hunger. ARD-101 is also being studied in hypothalamic obesity. Aardvark is also developing ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for the treatment of obesity and obesity-related conditions. For more information, visit aardvarktherapeutics.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning: Aardvark’s business strategy, product candidates, ongoing clinical trials, planned clinical trials, likelihood of success, as well as plans and objectives of management for future operations. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to potential delays in the commencement, enrollment and completion of clinical trials; the risk that we may use our capital resources sooner than expected and that they may be insufficient to allow us to achieve our anticipated milestones; risks related to our dependence on third parties for manufacturing, shipping and clinical and preclinical trials; the risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results; and other risks and uncertainties, including the factors discussed under the “Risk Factors” section of Aardvark’s Quarterly Report on Form 10-Q for the quarterended March 31, 2025, filed with the Securities and Exchange Commission on May 14, 2025. When evaluating Aardvark’s business and prospects, careful consideration should be given to these risks and uncertainties. Any forward-looking statements contained in this press release are based on the current expectations of Aardvark’s management team and speak only as of the date hereof, and Aardvark specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
Carolyn Hawley, Inizio Evoke Comms
(619) 849-5382
Carolyn.hawley@inizioevoke.com
FAQ
When and where is Aardvark Therapeutics (AARD) presenting at the 2025 United in Hope Conference?
What data will Aardvark Therapeutics (AARD) present about ARD-101?
What is the current development stage of Aardvark Therapeutics' (AARD) ARD-101 for PWS?
Who will represent Aardvark Therapeutics (AARD) at the conference?
